Purchase this article with an account.
S. Hohki, Y. Saishin, H. Mashimo, H. Haruta, H. Sakaguchi, M. Tsujikawa, N. Ohguro, Y. Tano; Systemic Administration of IL-6 Receptor Antibody Suppresses Choroidal Neovascularization (CNV) in Mice. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1745.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
It has previously been demonstrated that IL-6 is up-regulated by inducing CNV in the murine CNV tissues and IL-6-mediated angiogenesis is dependent on Vascular Endothelial Growth Factor (VEGF). Anti-mouse IL-6 receptor (IL-6R) antibody specifically binds to IL-6R and blocks IL-6 binding to IL-6R. This study sought to determine if systemic administration of IL-6R antibody could suppress CNV in the murine model.
Adult C57BL/6 mice were treated in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. The effect of subcutaneous injections of IL-6R antibody was tested in mice with laser-induced rupture of Bruch’s membrane at 3 locations in each eye. Mice received subcutaneous injections of 2mg of IL-6R antibody, or vehicle twice a week starting immediately after laser. Fourteen days after laser, mice were perfused with fluorescein-labeled dextran and the area of CNV at Bruch’s membrane rupture sites was measured on choroidal flat mounts by image analysis. For expression studies, mice were administrated IL-6R antibody or vehicle after laser. After 24 hours, mice were euthanized and eyes were dissected and homogenized followed by extraction of mRNA. RT-PCR was used to assess the effect of subcutaneous injection of IL-6R antibody on VEGF mRNA levels.
Compared to vehicle injections, subcutaneous injections of 2 mg of IL-6R antibody twice a week resulted in significant reductions in CNV area of 20%, (p<0.05). VEGF mRNA was decreased compared to vehicle injected mice.
These data confirm that IL-6R antibody may provide a new agent for treatment of patients with CNV.
This PDF is available to Subscribers Only